Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

[2011 news in infections diseases: selected readings].

Baumgartner JD, Christin L.

Rev Med Suisse. 2012 Jan 11;8(323):32-5. French.

PMID:
22303737
2.

[The chief internist of the general internal medicine department of a regional hospital: an endangered species?].

Baumgartner JD, Cometta A, Fumeaux T.

Rev Med Suisse. 2007 Nov 14;3(133):2579-80. French. No abstract available.

PMID:
18078186
3.

[Severe sepsis and septic shock].

Delaloye J, Baumgartner JD, Calandra T.

Rev Med Suisse. 2006 Apr 5;2(60):896-8, 900-2. Review. French.

PMID:
16673720
4.

Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media.

Bochud PY, Calandra T, Moreillon P, Baumgartner JD, Yersin B.

Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):136-7. No abstract available.

PMID:
11305469
5.

[Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].

Delarive P, Baumgartner JD, Glauser MP, Cometta A.

Schweiz Med Wochenschr. 2000 Dec 2;130(48):1837-44. French.

PMID:
11132527
6.

Treatment of sepsis: past and future avenues.

Baumgartner JD, Calandra T.

Drugs. 1999 Feb;57(2):127-32. Review.

PMID:
10188756
7.

Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia.

de Werra I, Jaccard C, Corradin SB, Chioléro R, Yersin B, Gallati H, Assicot M, Bohuon C, Baumgartner JD, Glauser MP, Heumann D.

Crit Care Med. 1997 Apr;25(4):607-13.

PMID:
9142024
8.

Sepsis and septic shock.

Zanetti G, Baumgartner JD, Glauser MP.

Schweiz Med Wochenschr. 1997 Mar 22;127(12):489-99. Review.

PMID:
9106949
9.

Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice.

Bailat S, Heumann D, Le Roy D, Baumgartner JD, Rietschel ET, Glauser MP, Di Padova F.

Infect Immun. 1997 Feb;65(2):811-4.

10.

[Treatment of severe infections: should one always administer an aminoglycoside?].

Cometta A, Baumgartner JD.

Schweiz Med Wochenschr Suppl. 1996;76:28S-33S. Review. French.

PMID:
8677416
11.

Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Cometta A, Baumgartner JD, Glauser MP.

Clin Exp Immunol. 1994 Jul;97 Suppl 1:69-72. Review.

12.

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.

Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, Schaad U, Herter C, Eggimann P, Huber O, et al.

Antimicrob Agents Chemother. 1994 Jun;38(6):1309-13.

13.

Pathogenesis and potential strategies for prevention and treatment of septic shock: an update.

Glauser MP, Heumann D, Baumgartner JD, Cohen J.

Clin Infect Dis. 1994 Feb;18 Suppl 2:S205-16. Review.

PMID:
8148464
14.

IFN-gamma involvement in the severity of gram-negative infections in mice.

Kohler J, Heumann D, Garotta G, LeRoy D, Bailat S, Barras C, Baumgartner JD, Glauser MP.

J Immunol. 1993 Jul 15;151(2):916-21.

PMID:
8335919
15.

Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes.

Heumann D, Gallay P, Betz-Corradin S, Barras C, Baumgartner JD, Glauser MP.

J Infect Dis. 1993 Jun;167(6):1351-7.

PMID:
8501324
16.

Short time exposure to lipopolysaccharide is sufficient to activate human monocytes.

Gallay P, Jongeneel CV, Barras C, Burnier M, Baumgartner JD, Glauser MP, Heumann D.

J Immunol. 1993 Jun 1;150(11):5086-93.

PMID:
7684419
17.

Immunotherapy of endotoxemia and septicemia.

Baumgartner JD, Glauser MP.

Immunobiology. 1993 Apr;187(3-5):464-77. Review.

PMID:
8330909
18.

[Cytokines and severe sepsis].

Baumgartner JD, Heumann D.

Rev Prat. 1993 Mar 1;43(5):559-63. Review. French.

PMID:
8341926
19.

Anti-endotoxin antibodies and other inhibitors of endotoxin.

Zanetti G, Glauser MP, Baumgartner JD.

New Horiz. 1993 Feb;1(1):110-9. Review.

PMID:
7922383
20.

Purification and characterization of murine lipopolysaccharide-binding protein.

Gallay P, Carrel S, Glauser MP, Barras C, Ulevitch RJ, Tobias PS, Baumgartner JD, Heumann D.

Infect Immun. 1993 Feb;61(2):378-83.

21.

A novel score for predicting the mortality of septic shock patients.

Baumgartner JD, Büla C, Vaney C, Wu MM, Eggimann P, Perret C.

Crit Care Med. 1992 Jul;20(7):953-60.

PMID:
1617989
22.

Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes.

Heumann D, Gallay P, Barras C, Zaech P, Ulevitch RJ, Tobias PS, Glauser MP, Baumgartner JD.

J Immunol. 1992 Jun 1;148(11):3505-12.

PMID:
1375247
23.

Anti-endotoxin therapy and the management of sepsis.

Baumgartner JD.

J Antimicrob Chemother. 1992 Apr;29(4):360-3. No abstract available.

PMID:
1607325
24.

Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide.

Zanetti G, Heumann D, Gérain J, Kohler J, Abbet P, Barras C, Lucas R, Glauser MP, Baumgartner JD.

J Immunol. 1992 Mar 15;148(6):1890-7.

PMID:
1541827
25.

Management of septic shock: new approaches.

Baumgartner JD, Eggimann P, Glauser MP.

Curr Clin Top Infect Dis. 1992;12:165-87. Review. No abstract available.

PMID:
1642798
26.

Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal.

Baumgartner JD.

Infect Dis Clin North Am. 1991 Dec;5(4):915-27. Review.

PMID:
1723740
27.

Anti-endotoxin antibody for prevention of acute GVHD.

Bayston K, Baumgartner JD, Clark P, Cohen J.

Bone Marrow Transplant. 1991 Nov;8(5):426-7. No abstract available.

PMID:
1768980
28.

Septic shock: pathogenesis.

Glauser MP, Zanetti G, Baumgartner JD, Cohen J.

Lancet. 1991 Sep 21;338(8769):732-6. Review. No abstract available.

PMID:
1679876
30.

[Anti-endotoxin monoclonal antibodies in the treatment of gram-negative germ sepsis].

Baumgartner JD.

Rev Prat. 1991 Jun 1;41(16):1479-82. French. No abstract available.

PMID:
1853112
31.

Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.

Baumgartner JD, Heumann D, Calandra T, Glauser MP.

J Infect Dis. 1991 Apr;163(4):769-72.

PMID:
2010630
32.

Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides.

Heumann D, Baumgartner JD, Jacot-Guillarmod H, Glauser MP.

J Infect Dis. 1991 Apr;163(4):762-8.

PMID:
1707084
33.

[What to do with a patient with multiple adenopathies?].

Baumgartner JD.

Rev Med Suisse Romande. 1991 Mar;111(3):215-7. French. No abstract available.

PMID:
2031119
34.

Anti-lipopolysaccharide antibodies in gram-negative bacteremia.

Baumgartner JD.

Behring Inst Mitt. 1991 Feb;(88):216-21. Review.

PMID:
2049041
35.
36.

Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.

Baumgartner JD.

Eur J Clin Microbiol Infect Dis. 1990 Oct;9(10):711-6. Review.

PMID:
2261915
37.

Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group.

Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP.

J Infect Dis. 1990 May;161(5):982-7.

PMID:
2109023
39.

[Do immunoglobulins have a value and a future in the treatment of severe bacterial infections?].

Baumgartner JD.

Presse Med. 1990 Feb 10;19(5):196-8. French. No abstract available.

PMID:
2137913
40.
41.

[Clinical spectrum of a common and insidious pathogen: Streptococcus milleri].

Spertini F, Baumgartner JD, Bille J.

Schweiz Med Wochenschr. 1988 Oct 1;118(39):1393-7. Review. French.

PMID:
3051341
42.

Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5.

Baumgartner JD, O'Brien TX, Kirkland TN, Glauser MP, Ziegler EJ.

J Infect Dis. 1987 Jul;156(1):136-43. Erratum in: J Infect Dis 1987 Dec;156(6):1043.

PMID:
2439613
43.

[Use of antibiotics for the prevention of bacterial pneumonia in surgical intensive care units].

Baumgartner JD, Glauser MP.

Schweiz Med Wochenschr. 1987 May 9;117(19):707-11. French.

PMID:
3589627
44.

Anti-endotoxin immunotherapy in septic shock.

Baumgartner JD, Glauser MP.

J Antimicrob Chemother. 1987 Apr;19(4):551. No abstract available.

PMID:
3583974
45.

[Indications for passive immunotherapy in infectious diseases].

Baumgartner JD.

Schweiz Med Wochenschr. 1987 Jan 17;117(3):84-90. French.

PMID:
3823822
46.

Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient.

Baumgartner JD, Glauser MP.

Rev Infect Dis. 1987 Jan-Feb;9(1):194-205. Review.

PMID:
3547572
47.

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, van Melle G, Klauber MR, Vogt M, Muehlen E, Luethy R, Chiolero R, et al.

Lancet. 1985 Jul 13;2(8446):59-63.

PMID:
2861523
48.

Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia.

Baumgartner JD, Glauser MP.

Am J Med. 1984 Oct 19;77(4C):54-8.

PMID:
6093520
49.

An extreme form of the hyperdynamic syndrome in septic shock.

Baumgartner JD, Vaney C, Perret C.

Intensive Care Med. 1984;10(5):245-9.

PMID:
6491037
50.

Comparative imipenem treatment of Staphylococcus aureus endocarditis in the rat.

Baumgartner JD, Glauser MP.

J Antimicrob Chemother. 1983 Dec;12 Suppl D:79-87.

PMID:
6583198

Supplemental Content

Loading ...
Support Center